A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Leniolisib (Primary)
- Indications Common variable immunodeficiency
- Focus Adverse reactions
- Sponsors Pharming Group NV
- 02 Apr 2025 New trial record